医管局:病情稳定的慢病患者,一次可开12周药!

2021-03-25 网络 网络

近日,国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组印发《关于做好当前慢性病长期用药处方管理工作的通知》。

近日,国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组印发《关于做好当前慢性病长期用药处方管理工作的通知》。《通知》强调,医疗机构要采取切实有效措施,满足需长期用药、血液透析等特殊治疗的慢性病患者的医疗服务需求,对病情稳定的慢性病患者,一次可开具12周以内相关药品。

加强日常医疗服务管理,鼓励结合本地实际,制订完善针对慢性病患者的长期处方管理政策,明确可开具长期处方的病种目录、用药范围、管理制度、安全告知等要求,减少患者取药次数。医疗机构要采取切实有效措施,满足需长期用药(包括麻醉药品、精神药品等特殊药品)、血液透析等特殊治疗的慢性病患者的医疗服务需求,对病情稳定的慢性病患者,一次可开具12周以内相关药品;必要的检验检查和常规复查等,可指导患者在就近的医疗机构进行,并通过电话随访等多种方式加强远程指导;应当加强对使用长期处方患者的用药教育,使其增加合理用药知识,提高自我用药管理能力和用药依从性,并告知患者在用药过程中出现任何不适,应当及时就诊。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-06-20 ms4000000639752186

    优秀!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-05-20 1e1e4967m20(暂无匿称)

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-05-20 1e1e4967m20(暂无匿称)

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 14716fd8m27暂无昵称

    学习了 谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 120f2af5m62暂无昵称

    不错

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2054281, encodeId=7307205428119, content=<a href='/topic/show?id=58f23522910' target=_blank style='color:#2F92EE;'>#医管局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35229, encryptionId=58f23522910, topicName=医管局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Thu Feb 17 20:02:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799563, encodeId=a7c01e995635d, content=<a href='/topic/show?id=f9b1e08715e' target=_blank style='color:#2F92EE;'>#病情稳定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70871, encryptionId=f9b1e08715e, topicName=病情稳定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Dec 16 06:02:56 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975053, encodeId=47609e505382, content=优秀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210620/96779e51d3bd4756819184871392d586/3b47730e383a4fc9803a21d92d6a18c5.jpg, createdBy=70d45340787, createdName=ms4000000639752186, createdTime=Sun Jun 20 09:35:21 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765137, encodeId=fc2e1e65137b1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 19 15:02:56 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967273, encodeId=91ed96e27388, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:06:49 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967267, encodeId=6b8e96e2677c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aacb2008540, createdName=1e1e4967m20(暂无匿称), createdTime=Thu May 20 17:00:11 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951225, encodeId=22c4951225fe, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c895190532, createdName=14716fd8m27暂无昵称, createdTime=Thu Mar 25 17:32:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951177, encodeId=7bd59511e7e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 25 16:39:17 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951157, encodeId=db1895115e07, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d462218675, createdName=120f2af5m62暂无昵称, createdTime=Thu Mar 25 16:06:33 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951059, encodeId=a5ab951059c3, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Mar 25 15:25:39 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 jyzxjiangqin

    好文章!

    0

相关资讯

全力打造慢病全病程管理创新模式,赛诺菲慢病管理创新项目落地浦东软件园

2020年11月8日,赛诺菲持续深入拓展与外部各界伙伴跨领域合作,全力打造具有中国特色、适合中国国情的慢病管理创新模式。

为什么慢病管理在中国不是金矿?

随着疾病谱的改变,慢病人群的快速增加正成为各国医疗体系的巨大负担。随着老龄化的进展,特别是主要经济体的少子化,医疗负担对医保和个人的开支形成了日益严重的压力,这也激发了市场对慢病管理的期待,希望通过防治结合的方式来降低慢病人群的开支特别是并发症的开支,以延缓医疗费用的增速。但是,慢病管理在全球都不能被产业化,无论是在商保高度发达的美国,还是在社会保障发达的其他主要经济体,慢病管理从来不是一个可独立

一文了解慢病管理实用App

Hello大家好,我是最近过敏寻麻疹痒到怀疑人生的柱子哥。这是我的第十篇文章。之前发父母在,远游心难安这篇文章后,有些旁友后台留言问如何用更方便的app管理病历信息,我这几天稍微研究了下移动医疗,结论是:对于C端患者来说,暂时没有兼具个人病历管理+医生出院管理+与医院HIS系统打通的多病种闭环工具,但是对于常见的慢病,有些病种细分垂直领域的app还是可以用一用来增加依从性和医患沟通效率的。大图

覆盖259家药企、28万家药店后,10岁的1药网要更聚焦慢病管理

“过去几年间,我们与药企的合作呈现出三级跳的态势。两年多前,我们只和60多家药企建立了合作,一年前增加到120多家,到现在已经与259家药企形成了战略合作。”在9月24日举办的

MMC打造多场景综合慢病管理模式,开启健康管理新时代

2019年5月10日,我国是糖尿病第一大国,多年来,糖尿病合并高血压、高血脂、冠心病是糖尿病综合管理的难点,也是糖尿病致死、致残的主要原因。国家标准化代谢性疾病管理中心(以下简称MMC)的成立和运行,本着以患者为中心的理念,为我国糖尿病防治带来变革性突破。在第一届MMC年会公布了患者代谢综合控制水平和血糖“金标准”达标率翻倍的“惊喜”成效:代谢综合达标率由基线的7.2%上升至17.3%,糖化达标率

生活方式干预将成慢病管理的下一个突破口?

随着老龄化趋势的日益加剧,以及不良生活方式的影响,如今慢性病已经成为国内居民的主要死亡原因和疾病负担。根据国家卫建委公布的数据,目前我国心脑血管疾病、癌症、慢性呼吸系统疾病、糖尿病等慢性非传染性疾病死

拓展阅读

重磅!曜影医疗推出新一代数字化慢病管理服务“曜健康”

随着生活水平的提高,糖尿病、高血压、高血脂等疾病的患病人数不断增多。据推算,中国心血管病现患人数超过3亿,直接导致各类心血管事件如脑梗或心梗的增加,且从以往的高龄人群中逐渐向中青年人群转移。对慢病的管

圆桌派第一期:风湿免疫科的慢病管理与临床科研

风湿免疫疾病因其长病程、长生存周期和高致残留率,常给病人带来极大痛苦,也给社会带来了巨大的经济负担。

FDA批准FreeStyle Libre 2 App用于糖尿病管理

糖尿病管理一直是慢病管理领域的热点。

全力打造慢病全病程管理创新模式,赛诺菲慢病管理创新项目落地浦东软件园

2020年11月8日,赛诺菲持续深入拓展与外部各界伙伴跨领域合作,全力打造具有中国特色、适合中国国情的慢病管理创新模式。

生活方式干预将成慢病管理的下一个突破口?

随着老龄化趋势的日益加剧,以及不良生活方式的影响,如今慢性病已经成为国内居民的主要死亡原因和疾病负担。根据国家卫建委公布的数据,目前我国心脑血管疾病、癌症、慢性呼吸系统疾病、糖尿病等慢性非传染性疾病死

覆盖259家药企、28万家药店后,10岁的1药网要更聚焦慢病管理

“过去几年间,我们与药企的合作呈现出三级跳的态势。两年多前,我们只和60多家药企建立了合作,一年前增加到120多家,到现在已经与259家药企形成了战略合作。”在9月24日举办的